Press Releases

Date Headline
8/4/2022
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
 Summary
Zanidatamab zovodotin (ZW49) accepted for oral presentation of Phase 1 clinical data at European Society for Medical Oncology (ESMO) Congress in September Announced Early Research and Development (eR&D) day presentation and webcast for October 20 th , 2022 with focus on TOPO1i antibody-drug  Continue Reading
8/1/2022
Zymeworks Announces Participation in Upcoming Investor Conferences
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Aug. 1, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: Citi’s 17  Continue Reading
7/25/2022
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
 Summary
Oral presentation will take place on Monday, September 12 at 5:25 pm Central European Summer Time (CEST) VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jul. 25, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today  Continue Reading
7/22/2022
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jul. 22, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the “NYSE  Continue Reading
7/21/2022
Zymeworks to Host Second Quarter Results Conference Call
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jul. 21, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its second quarter 2022 financial results after market close on  Continue Reading
7/15/2022
Zymeworks Announces Plan to Become a Delaware Corporation
 Summary
Enhances alignment with US shareholder base and other peer biotechnology companies Positions company for growth while helping to reduce complexity and certain administrative costs The Company’s name, brand, and ticker symbol to remain unchanged VANCOUVER, British Columbia & SEATTLE --(BUSINESS  Continue Reading
6/27/2022
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
 Summary
Dr. Moore will lead Zymeworks’ Early Research & Development Group   responsible for advancing the Company’s next-generation of multispecific antibody programs and antibody drug conjugate (ADC) programs into clinical studies VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jun.  Continue Reading
6/10/2022
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
 Summary
Plan ensures shareholders are protected and treated equitably Does not prevent the Zymeworks Board from engaging on future acquisition proposal that is in the best interests of all shareholders VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jun. 10, 2022-- Zymeworks Inc.  Continue Reading
5/27/2022
Zymeworks Announces Participation in Upcoming Investor Conference
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--May 27, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: Jefferies  Continue Reading
5/26/2022
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
 Summary
Study of zanidatamab in combination with docetaxel results in 90.5% confirmed objective response rate (cORR) in first-line treatment of advanced HER2-positive breast cancer Zanidatamab in combination with chemotherapy and tislelizumab shows 75.8% cORR and 100% disease control rate (DCR) in  Continue Reading
Displaying 1 - 10 of 29
Copyright 2022 , Zymeworks Inc.